The risk of prostate cancer for men on aspirin, statin or antidiabetic medications

European Journal of Cancer

Volumn 51, Issue 6, 2015, Pages 725-733

  Nordström, Tobias ^a,b   Clements, Mark ^b   Karlsson, Robert ^b   Adolfsson, Jan ^b   Grönberg, Henrik ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chemoprevention; Prostate neoplasia; Prostate specific antigen

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; PROSTATE SPECIFIC ANTIGEN; ROSUVASTATIN; SIMVASTATIN; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CLINICAL STUDY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; EDUCATIONAL STATUS; GLEASON SCORE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SWEDEN; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTOR;

ASPIRIN; COHORT STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SWEDEN;

EID: 84925356385     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.02.003     Document Type: Article

References (30)

1. National Board of Health and Welfare. Cancer Incidence in Sweden 2012. SocialstyrelsenSe n.d.
2. Engblom S. Samhällskostnader för cancer - år 2002 och år 2020. Cancerfonden 2003.
3. H.A. van Vugt, M.J. Roobol, R. Kranse, L. Maattanen, P. Finne, and J. Hugosson Prediction of prostate cancer in unscreened men: external validation of a risk calculator Eur J Cancer 47 2011 903 909
4. D.P. Ankerst, A. Boeck, S.J. Freedland, J.S. Jones, A.M. Cronin, and M.J. Roobol Evaluating the prostate cancer prevention trial high grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group World J Urol 32 2014 185 191
5. F.M.E. Wagenlehner, E. van Oostrum, P. Tenke, Z. Tandogdu, M. Çek, and M. Grabe Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study Eur Urol 63 2013 521 527
6. E.A.M. Heijnsdijk, E.M. Wever, A. Auvinen, J. Hugosson, S. Ciatto, and V. Nelen Quality-of-life effects of prostate-specific antigen screening N Engl J Med 367 2012 595 605
7. C. Bosetti, V. Rosato, S. Gallus, and C. La Vecchia Aspirin and urologic cancer risk: an update Nat Rev Urol 9 2012 102 110
8. Y. Liu, J.Q. Chen, L. Xie, J. Wang, L. Taije, and H. Yu Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis BMC Med 12 2013 55
9. P.M. Rothwell, F.G. Fowkes, J.F. Belch, H. Ogawa, C.P. Warlow, and T.W. Meade Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 2011 31 41
10. S.F. Nielsen, B.R.G. Nordestgaard, and S.E. Bojesen Statin use and reduced cancer-related mortality N Engl J Med 367 2012 1792 1802
11. A. Lustman, S. Nakar, A.D. Cohen, and S. Vinker Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study Prostate Cancer Prostatic Dis 17 2014 6 9
12. C.G. Jespersen, M. Nörgaard, S. Friis, C. Skriver, and M. Borre Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997-2010 Cancer Epidemiol 38 2014 42 47
13. T.J. Murtola, T.L.J. Tammela, L. Määttänen, H. Huhtala, E.A. Platz, and M. Ala-Opas Prostate cancer and PSA among statin users in the finnish prostate cancer screening trial Int J Cancer 127 2010 1650 1659
14. S.J. Freeland, R.J. Hamilton, L. Gerber, L.L. Banez, D.M. Moreira, and G.L. Andriole Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study Prostate Cancer Prostatic Dis 16 2013 254 259
15. E.A. Platz, C.M. Tangen, P.J. Goodman, C. Till, H.L. Parnes, and W.D. Figg Statin drug use is not associated with prostate cancer risk in men who are regularly screened J Urol 192 2014 379 384
16. D. Margel, D. Urbach, L.L. Lipscombe, C.M. Bell, G. Kulkami, and P.C. Austin Association between metformin use and risk of prostate cancer and its grade J Natl Cancer Inst 105 2013 1123 1131
17. D. Margel, D. Urbach, L.L. Lipscombe, C.M. Bell, G. Kulkami, and P.C. Austin Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes J Clin Oncol 31 2013 3069 3075
18. Z. Pengpeng, H. Li, X. Tan, L. Chen, and S. Wang Association of metformin use with cancer incidence and mortality: a meta-analysis Cancer Epidemiol 37 2013 207 218
19. T. Nordström, M. Aly, M.S. Clements, C.E. Weibull, J. Adolfsson, and H. Grönberg Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011 Eur Urol 63 2013 419 425
20. L. Barlow, K. Westergren, L. Holmberg, and M. Talback The completeness of the Swedish cancer register: a sample survey for year 1998 Acta Oncol 48 2009 27 33
21. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
22. A. Berglund, H. Garmo, C. Tishelman, L. Holmberg, P. Stattin, and M. Lambe Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden J Urol 185 2011 833 840
23. B. Wettermark, N. Hammar, M. Fored, A. Leimanis, P. Otterblad, and U. Bergman The new Swedish prescribed drug register-opportunities for pharmacoepidemiological research and experience from the first six months Pharmacoepidemiol Drug Saf 16 2007 726 735
24. World Health Organisation. Guidelines for ATC classification and DDD assignment. www.whocc.no 2005.
25. C. Bosetti, V. Rosato, S. Gallus, J. Cuzick, and C. La Vecchia Aspirin and cancer risk: a quantitative review to 2011 Ann Oncol 23 2012 1403 1415
26. P.K. Dhillon, S.A. Kenfield, M.J. Stampfer, and E.L. Giovannucci Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006 Int J Cancer 128 2011 2444 2452
27. T. Veitonmäki, T. Tammela, A. Auvinen, and T.J. Murtola Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level Eur J Cancer 49 2013 938 945
28. T.J. Murtola, T.L. Tammela, J. Lahtela, and A. Auvinen Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study Cancer Epidemiol Biomarkers Prev 16 2007 2226 2232
29. J. Morote, A. Celma, J. Planas, J. Placer, I. de Torres, and M. Olivan Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness Int J Mol Sci 15 8 2014 13615 13623
30. M. Randazzo, J. Beatrice, A. Huber, R. Grobholz, L. Manka, and S.F. Wyler Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau) World J Urol 2014 10.1007/s00345-014-1426-y